Tempest Therapeutics: appoints director John Frederick

What happened The filing says the Board of Directors appointed Mr. John Frederick as a Class III director of Tempest Therapeutics, effective Oct 13, 2026. Mr. Frederick will serve until the Company’s 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. The filing also says the Company issued a press release on Oct 14, 2026, announcing the appointment.

Key details

• Appointment effective Oct 13, 2026; term through the 2027 annual meeting.
• Mr. John Frederick, age 62, served as Chief Financial Officer of Skillsoft Corp. from May 2025 to Sep 2026 and as Chief Transformation Officer beginning Aug 2024; he has more than 30 years of leadership experience.
• As a non-employee director, he will be compensated under the Company’s Non-Employee Director Compensation Policy, including an initial option award to purchase 25,000 shares under the Company’s 2023 Equity Incentive Plan.
• Mr. Frederick entered into the Company’s standard form of indemnification agreement; the filing states there are no arrangements, family relationships or transactions requiring disclosure under Item 404(a) of Regulation S-K.

Why it may matter This item was reported under Item 5.02 (departure of directors or certain officers; election of directors) and Item 7.01 (Regulation FD disclosure for the press release). This filing does not show why the insider traded or why the company acted.